Risk of osteonecrosis in patients taking bisphosphonates for prevention of osteoporosis

A systematic review and meta-analysis

S. H. Lee, S. S. Chang, M. Lee, R. C. Chan, C. C. Lee

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

We aimed to systematically review observational studies evaluating use of bisphosphonates (BPs) and risk of osteonecrosis of jaw (ONJ) or other sites among non-cancer patients. Introduction: PubMed, EMBASE, and Cochrane Library were screened from database inception to Dec 2012. Methods: Two reviewers independently identified cohort and case-control studies evaluating the use of oral or intravenous (IV) BPs and the risk of ONJ and extracted the characteristics of the studies and risk estimates. Pooled estimates of odds ratios and 95 % confidence intervals (CI) were derived by random effects meta-analysis. Subgroup analyses were carried according to patients' characteristics and route of BP use. Results: We identified 12 studies, including 2,652 cases and 1,571,997 controls. Use of BPs was associated with a significantly increased risk of ONJ or ON of other sites [odds ratio (OR) 2.32; 95 % CI 1.38-3.91; I 2 = 91 %]. The summary OR was 2.91 (95 % CI 1.62-5.22; I 2 = 85.9 %) for adjusted studies. Use of BPs were associated with higher risk on ONJ (OR 2.57; 95 % CI 1.37-4.84; I 2 = 92.2 %) than ON of other sites (OR 1.79; 95 % CI 0.71-4.47; I 2 = 83.3 %). Meta-regression analysis did not find design characteristics or outcome definitions to be significant sources of heterogeneity. Conclusion: The available evidence suggests that use of BPs in cancer patients is associated with a substantial risk for ONJ. Patients receiving IV BP are at highest risk.

Original languageEnglish
Pages (from-to)1131-1139
Number of pages9
JournalOsteoporosis International
Volume25
Issue number3
DOIs
Publication statusPublished - Mar 1 2014
Externally publishedYes

Fingerprint

Osteonecrosis
Diphosphonates
Osteoporosis
Meta-Analysis
Jaw
Odds Ratio
Confidence Intervals
Bisphosphonate-Associated Osteonecrosis of the Jaw
PubMed
Libraries
Observational Studies
Case-Control Studies
Regression Analysis
Databases
Neoplasms

Keywords

  • Bisphosphonate
  • Osteonecrosis
  • Osteoporosis

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Risk of osteonecrosis in patients taking bisphosphonates for prevention of osteoporosis : A systematic review and meta-analysis. / Lee, S. H.; Chang, S. S.; Lee, M.; Chan, R. C.; Lee, C. C.

In: Osteoporosis International, Vol. 25, No. 3, 01.03.2014, p. 1131-1139.

Research output: Contribution to journalArticle

@article{3f0249e60aa144f7a9f32974321090de,
title = "Risk of osteonecrosis in patients taking bisphosphonates for prevention of osteoporosis: A systematic review and meta-analysis",
abstract = "We aimed to systematically review observational studies evaluating use of bisphosphonates (BPs) and risk of osteonecrosis of jaw (ONJ) or other sites among non-cancer patients. Introduction: PubMed, EMBASE, and Cochrane Library were screened from database inception to Dec 2012. Methods: Two reviewers independently identified cohort and case-control studies evaluating the use of oral or intravenous (IV) BPs and the risk of ONJ and extracted the characteristics of the studies and risk estimates. Pooled estimates of odds ratios and 95 {\%} confidence intervals (CI) were derived by random effects meta-analysis. Subgroup analyses were carried according to patients' characteristics and route of BP use. Results: We identified 12 studies, including 2,652 cases and 1,571,997 controls. Use of BPs was associated with a significantly increased risk of ONJ or ON of other sites [odds ratio (OR) 2.32; 95 {\%} CI 1.38-3.91; I 2 = 91 {\%}]. The summary OR was 2.91 (95 {\%} CI 1.62-5.22; I 2 = 85.9 {\%}) for adjusted studies. Use of BPs were associated with higher risk on ONJ (OR 2.57; 95 {\%} CI 1.37-4.84; I 2 = 92.2 {\%}) than ON of other sites (OR 1.79; 95 {\%} CI 0.71-4.47; I 2 = 83.3 {\%}). Meta-regression analysis did not find design characteristics or outcome definitions to be significant sources of heterogeneity. Conclusion: The available evidence suggests that use of BPs in cancer patients is associated with a substantial risk for ONJ. Patients receiving IV BP are at highest risk.",
keywords = "Bisphosphonate, Osteonecrosis, Osteoporosis",
author = "Lee, {S. H.} and Chang, {S. S.} and M. Lee and Chan, {R. C.} and Lee, {C. C.}",
year = "2014",
month = "3",
day = "1",
doi = "10.1007/s00198-013-2575-3",
language = "English",
volume = "25",
pages = "1131--1139",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "3",

}

TY - JOUR

T1 - Risk of osteonecrosis in patients taking bisphosphonates for prevention of osteoporosis

T2 - A systematic review and meta-analysis

AU - Lee, S. H.

AU - Chang, S. S.

AU - Lee, M.

AU - Chan, R. C.

AU - Lee, C. C.

PY - 2014/3/1

Y1 - 2014/3/1

N2 - We aimed to systematically review observational studies evaluating use of bisphosphonates (BPs) and risk of osteonecrosis of jaw (ONJ) or other sites among non-cancer patients. Introduction: PubMed, EMBASE, and Cochrane Library were screened from database inception to Dec 2012. Methods: Two reviewers independently identified cohort and case-control studies evaluating the use of oral or intravenous (IV) BPs and the risk of ONJ and extracted the characteristics of the studies and risk estimates. Pooled estimates of odds ratios and 95 % confidence intervals (CI) were derived by random effects meta-analysis. Subgroup analyses were carried according to patients' characteristics and route of BP use. Results: We identified 12 studies, including 2,652 cases and 1,571,997 controls. Use of BPs was associated with a significantly increased risk of ONJ or ON of other sites [odds ratio (OR) 2.32; 95 % CI 1.38-3.91; I 2 = 91 %]. The summary OR was 2.91 (95 % CI 1.62-5.22; I 2 = 85.9 %) for adjusted studies. Use of BPs were associated with higher risk on ONJ (OR 2.57; 95 % CI 1.37-4.84; I 2 = 92.2 %) than ON of other sites (OR 1.79; 95 % CI 0.71-4.47; I 2 = 83.3 %). Meta-regression analysis did not find design characteristics or outcome definitions to be significant sources of heterogeneity. Conclusion: The available evidence suggests that use of BPs in cancer patients is associated with a substantial risk for ONJ. Patients receiving IV BP are at highest risk.

AB - We aimed to systematically review observational studies evaluating use of bisphosphonates (BPs) and risk of osteonecrosis of jaw (ONJ) or other sites among non-cancer patients. Introduction: PubMed, EMBASE, and Cochrane Library were screened from database inception to Dec 2012. Methods: Two reviewers independently identified cohort and case-control studies evaluating the use of oral or intravenous (IV) BPs and the risk of ONJ and extracted the characteristics of the studies and risk estimates. Pooled estimates of odds ratios and 95 % confidence intervals (CI) were derived by random effects meta-analysis. Subgroup analyses were carried according to patients' characteristics and route of BP use. Results: We identified 12 studies, including 2,652 cases and 1,571,997 controls. Use of BPs was associated with a significantly increased risk of ONJ or ON of other sites [odds ratio (OR) 2.32; 95 % CI 1.38-3.91; I 2 = 91 %]. The summary OR was 2.91 (95 % CI 1.62-5.22; I 2 = 85.9 %) for adjusted studies. Use of BPs were associated with higher risk on ONJ (OR 2.57; 95 % CI 1.37-4.84; I 2 = 92.2 %) than ON of other sites (OR 1.79; 95 % CI 0.71-4.47; I 2 = 83.3 %). Meta-regression analysis did not find design characteristics or outcome definitions to be significant sources of heterogeneity. Conclusion: The available evidence suggests that use of BPs in cancer patients is associated with a substantial risk for ONJ. Patients receiving IV BP are at highest risk.

KW - Bisphosphonate

KW - Osteonecrosis

KW - Osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=84894554789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894554789&partnerID=8YFLogxK

U2 - 10.1007/s00198-013-2575-3

DO - 10.1007/s00198-013-2575-3

M3 - Article

VL - 25

SP - 1131

EP - 1139

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 3

ER -